http://www.bna.com/trinity-health-settles-n73014445765/


The following hospital mergers, acquisitions and general transactions took place or were announced in August.

As part of a management agreement, Leadville, Colo.-based St. Vincent General Hospital and Englewood, Colo.-based Centura Health, will jointly plan, develop and build a healthcare facility in Lake County, Colo.
Under the management agreement, St. Vincent General Hospital, a 25-bed critical access hospital, is integrating with operations at Centura Health. The construction of the Lake County hospital is part of an expansion of that agreement.
Additionally, under the expanded agreement:

Tacoma, Wash.-based CHI Franciscan Health has submitted a letter of intent to the Washington State Department of Health requesting regulatory approval to invest in a new hospital at Harrison Medical Center-Silverdale (Wash.). The LOI is the first step in the certificate of need application.
CHI Franciscan Health, which affiliated with Harrison Medical Center in 2014, plans to invest more than $530 million on the expansion project. The project will be divided into two phases.
Phase one, which will cost $283 million, will involve the transfer of 168 inpatient beds from the Harrison Medical Center-Bremerton (Wash.) license while retaining 85 licensed beds at Bremerton. Harrison Medical Center-Bremerton, which houses 253 beds, will close after the completion of phase one in Silverdale.
The second phase will add the rest of the beds, based on demand, and is expected to cost $201 million.
CHI Franciscan Health plans to submit the full CON application to state regulators later this year.


Superbug resistant to two last-resort antibiotics found in US for first time

A strain of E. coli resistant to two last-resort antibiotics has for the first time been reported in the United States.
The strain was found in the urine of a man treated at a New Jersey hospital two years ago. It was tested in 2016 as part of a larger analysis of bacteria from the hospital.
For hard-to-treat bacteria infections, the antibiotics colistin and carbapenem are considered the big guns — a last line of defense when nothing else is working. In recent months mcr-1, a gene which confers resistance to colistin, has been found in E. coli from over 30 countries, including bacteria isolated from pigs and people in China and a patient in New York City.
Similarly the gene blaNDM-5 renders the antibiotic carbapenem useless against its bacterial carrier. In 2012, the Centers for Disease Control and Prevention found carbapenem-resistant bacteria in about 4 percent of US hospitals.
Researchers and health officials have feared the joining of these two genes in a single bacterial strain, as it could set the stage for the rise of superbugs that can’t be treated with our current arsenal of drugs. The combination has been detected before in other countries, including Germany, Venezuela, and China, but until now, it has never been seen within the United States.